| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Magnetic Resonance Imaging | 156 | 2026 | 3651 | 13.720 |
Why?
|
| Contrast Media | 88 | 2026 | 1096 | 10.430 |
Why?
|
| Prostatic Neoplasms | 61 | 2025 | 1798 | 7.590 |
Why?
|
| Image Enhancement | 35 | 2023 | 565 | 4.980 |
Why?
|
| Breast Neoplasms | 45 | 2026 | 3147 | 4.540 |
Why?
|
| Breast | 25 | 2025 | 297 | 4.050 |
Why?
|
| Prostate | 24 | 2025 | 423 | 3.670 |
Why?
|
| Image Interpretation, Computer-Assisted | 29 | 2025 | 703 | 3.580 |
Why?
|
| Image Processing, Computer-Assisted | 26 | 2026 | 1323 | 3.480 |
Why?
|
| Diffusion Magnetic Resonance Imaging | 24 | 2024 | 301 | 3.240 |
Why?
|
| Mammary Neoplasms, Experimental | 17 | 2015 | 133 | 3.110 |
Why?
|
| Gadolinium DTPA | 32 | 2017 | 255 | 2.530 |
Why?
|
| Signal-To-Noise Ratio | 10 | 2025 | 115 | 2.480 |
Why?
|
| Algorithms | 21 | 2025 | 2014 | 2.420 |
Why?
|
| Mammary Glands, Animal | 8 | 2020 | 81 | 2.360 |
Why?
|
| Neoadjuvant Therapy | 4 | 2026 | 444 | 1.660 |
Why?
|
| Phantoms, Imaging | 11 | 2024 | 491 | 1.650 |
Why?
|
| Carcinoma, Intraductal, Noninfiltrating | 7 | 2017 | 126 | 1.620 |
Why?
|
| Mammary Neoplasms, Animal | 5 | 2020 | 58 | 1.620 |
Why?
|
| Reproducibility of Results | 37 | 2024 | 2883 | 1.570 |
Why?
|
| Water | 14 | 2023 | 307 | 1.460 |
Why?
|
| Magnetic Resonance Spectroscopy | 27 | 2018 | 325 | 1.450 |
Why?
|
| Echo-Planar Imaging | 11 | 2020 | 52 | 1.430 |
Why?
|
| Imaging, Three-Dimensional | 10 | 2020 | 630 | 1.350 |
Why?
|
| Gadolinium | 8 | 2019 | 106 | 1.290 |
Why?
|
| Fourier Analysis | 7 | 2016 | 128 | 1.160 |
Why?
|
| Arteries | 3 | 2020 | 181 | 1.140 |
Why?
|
| Diet, High-Fat | 2 | 2020 | 135 | 1.120 |
Why?
|
| Neovascularization, Pathologic | 10 | 2015 | 355 | 1.110 |
Why?
|
| Triple Negative Breast Neoplasms | 3 | 2020 | 184 | 1.080 |
Why?
|
| Humans | 137 | 2026 | 96127 | 1.060 |
Why?
|
| Sensitivity and Specificity | 29 | 2023 | 2040 | 1.020 |
Why?
|
| Organometallic Compounds | 9 | 2021 | 148 | 1.020 |
Why?
|
| Carcinogenesis | 2 | 2020 | 237 | 1.010 |
Why?
|
| Animals | 83 | 2022 | 28945 | 1.010 |
Why?
|
| Female | 85 | 2026 | 50063 | 1.000 |
Why?
|
| Magnetic Resonance Angiography | 3 | 2020 | 277 | 0.990 |
Why?
|
| Middle Aged | 68 | 2026 | 28363 | 0.970 |
Why?
|
| Rats | 41 | 2018 | 4154 | 0.950 |
Why?
|
| Male | 80 | 2025 | 45870 | 0.930 |
Why?
|
| Artifacts | 4 | 2023 | 252 | 0.900 |
Why?
|
| Neoplasm Transplantation | 19 | 2015 | 413 | 0.870 |
Why?
|
| Oxygen | 13 | 2021 | 788 | 0.850 |
Why?
|
| Mice | 36 | 2022 | 12562 | 0.810 |
Why?
|
| Muscle, Skeletal | 9 | 2014 | 483 | 0.770 |
Why?
|
| Aged | 50 | 2026 | 20964 | 0.760 |
Why?
|
| Meglumine | 5 | 2021 | 38 | 0.710 |
Why?
|
| Receptor, ErbB-2 | 1 | 2023 | 280 | 0.700 |
Why?
|
| Adult | 45 | 2026 | 28718 | 0.630 |
Why?
|
| Carcinoma, Ductal, Breast | 4 | 2014 | 166 | 0.630 |
Why?
|
| Fibroadenoma | 1 | 2019 | 9 | 0.620 |
Why?
|
| Tomography, X-Ray Computed | 5 | 2022 | 2781 | 0.610 |
Why?
|
| Retrospective Studies | 26 | 2026 | 10286 | 0.600 |
Why?
|
| Prospective Studies | 19 | 2025 | 4671 | 0.590 |
Why?
|
| Pilot Projects | 11 | 2021 | 938 | 0.580 |
Why?
|
| Feasibility Studies | 10 | 2019 | 819 | 0.580 |
Why?
|
| Prostatectomy | 13 | 2023 | 480 | 0.570 |
Why?
|
| Carbon Dioxide | 6 | 2002 | 212 | 0.560 |
Why?
|
| Dietary Sugars | 1 | 2018 | 8 | 0.560 |
Why?
|
| Proton Magnetic Resonance Spectroscopy | 1 | 2018 | 12 | 0.560 |
Why?
|
| Diet, Fat-Restricted | 1 | 2018 | 30 | 0.550 |
Why?
|
| Diagnosis, Differential | 15 | 2022 | 1619 | 0.550 |
Why?
|
| Feeding Behavior | 1 | 2020 | 338 | 0.540 |
Why?
|
| Rhabdomyosarcoma | 3 | 2003 | 44 | 0.530 |
Why?
|
| Carcinoma in Situ | 2 | 2015 | 53 | 0.530 |
Why?
|
| Vanadium | 2 | 2015 | 13 | 0.530 |
Why?
|
| Mammography | 5 | 2018 | 475 | 0.530 |
Why?
|
| Adipose Tissue | 4 | 2017 | 270 | 0.520 |
Why?
|
| Biopsy | 12 | 2022 | 1220 | 0.520 |
Why?
|
| Models, Biological | 11 | 2015 | 1815 | 0.520 |
Why?
|
| Mice, Transgenic | 7 | 2018 | 1645 | 0.520 |
Why?
|
| Fatty Acids | 1 | 2018 | 153 | 0.510 |
Why?
|
| Hyperthermia, Induced | 2 | 2020 | 75 | 0.510 |
Why?
|
| Microvessels | 3 | 2018 | 74 | 0.500 |
Why?
|
| Dietary Fats | 1 | 2017 | 137 | 0.500 |
Why?
|
| Adenocarcinoma | 7 | 2002 | 1215 | 0.500 |
Why?
|
| Microscopy, Fluorescence | 3 | 2015 | 444 | 0.500 |
Why?
|
| Neoplasm Invasiveness | 5 | 2020 | 590 | 0.490 |
Why?
|
| Laser Therapy | 4 | 2020 | 151 | 0.490 |
Why?
|
| Rats, Inbred F344 | 15 | 2005 | 165 | 0.480 |
Why?
|
| Hindlimb | 9 | 2010 | 97 | 0.480 |
Why?
|
| Subtraction Technique | 5 | 2009 | 130 | 0.480 |
Why?
|
| Motion | 4 | 2024 | 99 | 0.470 |
Why?
|
| Computer Simulation | 16 | 2021 | 1158 | 0.470 |
Why?
|
| Body Water | 5 | 2004 | 35 | 0.460 |
Why?
|
| Disease Models, Animal | 11 | 2020 | 2551 | 0.450 |
Why?
|
| Electron Probe Microanalysis | 1 | 2015 | 8 | 0.450 |
Why?
|
| Prostatic Hyperplasia | 4 | 2019 | 97 | 0.440 |
Why?
|
| Neoplasms | 10 | 2020 | 3250 | 0.430 |
Why?
|
| Kinetics | 8 | 2023 | 1562 | 0.420 |
Why?
|
| Fluorocarbons | 3 | 2005 | 72 | 0.420 |
Why?
|
| ROC Curve | 10 | 2025 | 797 | 0.420 |
Why?
|
| Multimodal Imaging | 2 | 2018 | 115 | 0.410 |
Why?
|
| Neoplasms, Experimental | 4 | 2005 | 271 | 0.410 |
Why?
|
| Oxides | 3 | 2002 | 44 | 0.390 |
Why?
|
| Ultrasonography | 2 | 2014 | 744 | 0.370 |
Why?
|
| Iron | 3 | 2002 | 179 | 0.370 |
Why?
|
| Brain | 12 | 2023 | 2482 | 0.350 |
Why?
|
| Neoplasm Grading | 7 | 2023 | 404 | 0.350 |
Why?
|
| Tumor Hypoxia | 2 | 2022 | 43 | 0.350 |
Why?
|
| Tumor Burden | 5 | 2020 | 323 | 0.340 |
Why?
|
| Blood Vessels | 1 | 2011 | 92 | 0.340 |
Why?
|
| X-Ray Microtomography | 1 | 2011 | 102 | 0.330 |
Why?
|
| Time Factors | 14 | 2018 | 5585 | 0.320 |
Why?
|
| Diagnostic Imaging | 1 | 2014 | 475 | 0.320 |
Why?
|
| Radiation-Sensitizing Agents | 3 | 2000 | 100 | 0.320 |
Why?
|
| Models, Theoretical | 6 | 2018 | 503 | 0.320 |
Why?
|
| Camellia sinensis | 1 | 2009 | 6 | 0.310 |
Why?
|
| Angiogenesis Modulating Agents | 1 | 2009 | 4 | 0.310 |
Why?
|
| Endocrine Gland Neoplasms | 1 | 2009 | 7 | 0.300 |
Why?
|
| Pentetic Acid | 3 | 1997 | 25 | 0.290 |
Why?
|
| Breast Diseases | 2 | 2011 | 101 | 0.290 |
Why?
|
| Fluorine | 2 | 2005 | 17 | 0.290 |
Why?
|
| Early Detection of Cancer | 2 | 2025 | 484 | 0.270 |
Why?
|
| Plant Extracts | 1 | 2009 | 248 | 0.270 |
Why?
|
| Adenosine Triphosphate | 10 | 1992 | 329 | 0.260 |
Why?
|
| Injections | 3 | 2017 | 126 | 0.260 |
Why?
|
| Image-Guided Biopsy | 2 | 2025 | 81 | 0.250 |
Why?
|
| Hyperoxia | 2 | 1997 | 37 | 0.250 |
Why?
|
| Magnetic Resonance Imaging, Interventional | 2 | 2018 | 34 | 0.240 |
Why?
|
| Regional Blood Flow | 4 | 2020 | 198 | 0.240 |
Why?
|
| Fructose | 3 | 2018 | 36 | 0.230 |
Why?
|
| Carcinoma | 1 | 2008 | 449 | 0.230 |
Why?
|
| Sarcoma, Experimental | 5 | 1992 | 53 | 0.220 |
Why?
|
| Misonidazole | 2 | 2022 | 18 | 0.220 |
Why?
|
| Cluster Analysis | 1 | 2026 | 392 | 0.220 |
Why?
|
| Dose-Response Relationship, Drug | 3 | 2019 | 1973 | 0.220 |
Why?
|
| Muscle Neoplasms | 1 | 2004 | 17 | 0.210 |
Why?
|
| Angiogenesis Inhibitors | 4 | 2016 | 299 | 0.210 |
Why?
|
| Carcinoma, Squamous Cell | 3 | 2022 | 1105 | 0.210 |
Why?
|
| Biomarkers, Tumor | 4 | 2015 | 1665 | 0.210 |
Why?
|
| Reference Values | 3 | 2015 | 675 | 0.200 |
Why?
|
| Aging | 1 | 2008 | 766 | 0.200 |
Why?
|
| Radiotherapy Planning, Computer-Assisted | 1 | 2024 | 204 | 0.200 |
Why?
|
| Cell Line, Tumor | 6 | 2015 | 2794 | 0.200 |
Why?
|
| Metabolic Clearance Rate | 4 | 2015 | 119 | 0.190 |
Why?
|
| Antigens, Polyomavirus Transforming | 2 | 2015 | 48 | 0.190 |
Why?
|
| White Matter | 2 | 2020 | 96 | 0.190 |
Why?
|
| Kidney Neoplasms | 3 | 2016 | 558 | 0.180 |
Why?
|
| Radiology | 2 | 2023 | 206 | 0.180 |
Why?
|
| Mice, Inbred C3H | 3 | 2020 | 372 | 0.180 |
Why?
|
| Mobile Applications | 1 | 2023 | 79 | 0.180 |
Why?
|
| Disease Progression | 4 | 2016 | 1568 | 0.180 |
Why?
|
| Magnets | 1 | 2021 | 12 | 0.180 |
Why?
|
| Positron-Emission Tomography | 3 | 2022 | 354 | 0.170 |
Why?
|
| Mice, Nude | 5 | 2011 | 842 | 0.170 |
Why?
|
| Colonic Neoplasms | 3 | 2015 | 589 | 0.170 |
Why?
|
| Breast Density | 2 | 2020 | 37 | 0.170 |
Why?
|
| Electron Spin Resonance Spectroscopy | 5 | 2022 | 329 | 0.170 |
Why?
|
| Phosphates | 4 | 1991 | 167 | 0.160 |
Why?
|
| Prognosis | 3 | 2026 | 4033 | 0.160 |
Why?
|
| Tumor Cells, Cultured | 5 | 2004 | 1054 | 0.160 |
Why?
|
| Young Adult | 3 | 2019 | 7025 | 0.160 |
Why?
|
| Myelin Sheath | 1 | 2020 | 85 | 0.160 |
Why?
|
| Aged, 80 and over | 11 | 2024 | 7232 | 0.160 |
Why?
|
| Treatment Outcome | 8 | 2023 | 9173 | 0.160 |
Why?
|
| Protons | 4 | 2018 | 104 | 0.150 |
Why?
|
| Indicator Dilution Techniques | 1 | 2019 | 9 | 0.150 |
Why?
|
| Organ Size | 1 | 2020 | 379 | 0.150 |
Why?
|
| Colitis | 2 | 2014 | 262 | 0.150 |
Why?
|
| Biological Transport | 2 | 2018 | 412 | 0.150 |
Why?
|
| Spin Labels | 3 | 2015 | 107 | 0.150 |
Why?
|
| Injections, Intravenous | 3 | 2015 | 238 | 0.150 |
Why?
|
| Liver | 9 | 2013 | 1238 | 0.150 |
Why?
|
| Hemoglobin A | 1 | 1998 | 8 | 0.140 |
Why?
|
| Information Storage and Retrieval | 2 | 2010 | 127 | 0.140 |
Why?
|
| Myocardium | 3 | 2006 | 596 | 0.140 |
Why?
|
| Urinary Bladder Neck Obstruction | 1 | 2017 | 26 | 0.130 |
Why?
|
| Random Allocation | 1 | 2018 | 327 | 0.130 |
Why?
|
| Weaning | 1 | 2017 | 26 | 0.130 |
Why?
|
| Ferrosoferric Oxide | 3 | 2002 | 19 | 0.130 |
Why?
|
| Edema | 2 | 2014 | 73 | 0.130 |
Why?
|
| Magnetite Nanoparticles | 3 | 2002 | 27 | 0.130 |
Why?
|
| Dextrans | 3 | 2002 | 78 | 0.130 |
Why?
|
| Radiographic Image Interpretation, Computer-Assisted | 1 | 2020 | 472 | 0.130 |
Why?
|
| Glycolysis | 2 | 2015 | 192 | 0.130 |
Why?
|
| BRCA1 Protein | 1 | 2018 | 215 | 0.130 |
Why?
|
| Adiposity | 1 | 2017 | 80 | 0.130 |
Why?
|
| Oxygen Consumption | 2 | 1995 | 257 | 0.130 |
Why?
|
| Time | 1 | 2016 | 79 | 0.120 |
Why?
|
| Radiography | 3 | 2015 | 826 | 0.120 |
Why?
|
| Follow-Up Studies | 1 | 2023 | 3927 | 0.120 |
Why?
|
| Prostatitis | 1 | 2015 | 14 | 0.120 |
Why?
|
| Simian virus 40 | 1 | 2015 | 36 | 0.120 |
Why?
|
| Indoles | 3 | 2007 | 317 | 0.120 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2026 | 2642 | 0.110 |
Why?
|
| Perfusion | 2 | 2014 | 266 | 0.110 |
Why?
|
| Signal Processing, Computer-Assisted | 4 | 2006 | 205 | 0.110 |
Why?
|
| Electromagnetic Fields | 1 | 1995 | 28 | 0.110 |
Why?
|
| Phosphorus | 8 | 1992 | 119 | 0.110 |
Why?
|
| Area Under Curve | 5 | 2018 | 340 | 0.110 |
Why?
|
| Niacinamide | 2 | 2012 | 102 | 0.110 |
Why?
|
| Receptor Cross-Talk | 1 | 2014 | 33 | 0.110 |
Why?
|
| Phenylurea Compounds | 2 | 2012 | 99 | 0.110 |
Why?
|
| Deuterium | 2 | 2008 | 35 | 0.110 |
Why?
|
| Electric Injuries | 1 | 1994 | 21 | 0.110 |
Why?
|
| Mitochondrial Proteins | 1 | 2015 | 129 | 0.110 |
Why?
|
| Spectrophotometry | 2 | 2018 | 108 | 0.110 |
Why?
|
| Anatomic Landmarks | 1 | 2014 | 31 | 0.110 |
Why?
|
| Calcinosis | 1 | 2015 | 232 | 0.110 |
Why?
|
| Soft Tissue Neoplasms | 1 | 1995 | 126 | 0.110 |
Why?
|
| Renin-Angiotensin System | 1 | 2014 | 84 | 0.110 |
Why?
|
| Sulfonamides | 1 | 2016 | 338 | 0.110 |
Why?
|
| Color | 1 | 2014 | 87 | 0.100 |
Why?
|
| Radiation, Ionizing | 1 | 2014 | 124 | 0.100 |
Why?
|
| Pyrimidines | 1 | 2016 | 386 | 0.100 |
Why?
|
| Receptors, Calcitriol | 1 | 2014 | 131 | 0.100 |
Why?
|
| Neoplasm Staging | 2 | 2018 | 2081 | 0.100 |
Why?
|
| Hot Temperature | 1 | 2014 | 217 | 0.100 |
Why?
|
| Reference Standards | 2 | 2012 | 150 | 0.100 |
Why?
|
| Mass Screening | 1 | 2018 | 710 | 0.100 |
Why?
|
| Mice, Knockout | 2 | 2015 | 2163 | 0.100 |
Why?
|
| Rabbits | 1 | 2014 | 639 | 0.100 |
Why?
|
| Radio Waves | 3 | 2002 | 20 | 0.100 |
Why?
|
| Fructosephosphates | 2 | 1989 | 3 | 0.100 |
Why?
|
| Software | 1 | 2017 | 698 | 0.100 |
Why?
|
| Enterocolitis, Necrotizing | 1 | 2013 | 82 | 0.100 |
Why?
|
| Cell Hypoxia | 3 | 2022 | 188 | 0.090 |
Why?
|
| Crohn Disease | 2 | 2009 | 806 | 0.090 |
Why?
|
| Deoxyglucose | 1 | 1992 | 39 | 0.090 |
Why?
|
| Ultrasonics | 1 | 2012 | 38 | 0.090 |
Why?
|
| Biomimetic Materials | 1 | 2012 | 26 | 0.090 |
Why?
|
| Fats | 1 | 2011 | 12 | 0.090 |
Why?
|
| Blood Pressure | 4 | 2000 | 929 | 0.090 |
Why?
|
| Ultrasonic Therapy | 1 | 2012 | 44 | 0.090 |
Why?
|
| Lymph Nodes | 1 | 2015 | 565 | 0.090 |
Why?
|
| Hydrodynamics | 2 | 2022 | 20 | 0.090 |
Why?
|
| ErbB Receptors | 1 | 2014 | 513 | 0.090 |
Why?
|
| Prostate-Specific Antigen | 1 | 2013 | 346 | 0.090 |
Why?
|
| High-Intensity Focused Ultrasound Ablation | 1 | 2012 | 48 | 0.090 |
Why?
|
| Platelet Endothelial Cell Adhesion Molecule-1 | 1 | 2011 | 48 | 0.090 |
Why?
|
| Neoplasm Metastasis | 4 | 2016 | 1103 | 0.090 |
Why?
|
| Molecular Weight | 2 | 2004 | 333 | 0.090 |
Why?
|
| Fluorescence | 1 | 2011 | 106 | 0.080 |
Why?
|
| Diagnosis, Computer-Assisted | 1 | 2013 | 341 | 0.080 |
Why?
|
| Oils | 1 | 2010 | 7 | 0.080 |
Why?
|
| Angiography | 1 | 2011 | 209 | 0.080 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2012 | 209 | 0.080 |
Why?
|
| Doxorubicin | 2 | 2022 | 304 | 0.080 |
Why?
|
| Protein Kinase Inhibitors | 2 | 2012 | 611 | 0.080 |
Why?
|
| Extremities | 1 | 2011 | 179 | 0.080 |
Why?
|
| Vanadates | 1 | 2009 | 32 | 0.080 |
Why?
|
| Adolescent | 2 | 2019 | 9896 | 0.080 |
Why?
|
| Insulin | 2 | 1992 | 1190 | 0.080 |
Why?
|
| Extracellular Space | 1 | 2009 | 90 | 0.080 |
Why?
|
| Enteritis | 1 | 2009 | 23 | 0.070 |
Why?
|
| Intestine, Large | 1 | 1989 | 15 | 0.070 |
Why?
|
| Fibrosarcoma | 2 | 2002 | 90 | 0.070 |
Why?
|
| Perfusion Imaging | 1 | 2009 | 52 | 0.070 |
Why?
|
| Fingers | 1 | 1989 | 70 | 0.070 |
Why?
|
| Radiotherapy, Conformal | 1 | 2009 | 89 | 0.070 |
Why?
|
| Jejunum | 1 | 1989 | 80 | 0.070 |
Why?
|
| Membrane Proteins | 1 | 2015 | 1276 | 0.070 |
Why?
|
| Phosphocreatine | 5 | 1991 | 14 | 0.070 |
Why?
|
| Benzenesulfonates | 1 | 2008 | 50 | 0.070 |
Why?
|
| Models, Statistical | 2 | 2010 | 594 | 0.070 |
Why?
|
| Ileum | 1 | 1989 | 169 | 0.070 |
Why?
|
| Microscopy | 1 | 2008 | 91 | 0.070 |
Why?
|
| Lung Neoplasms | 3 | 2015 | 2463 | 0.070 |
Why?
|
| Sulfones | 1 | 2007 | 46 | 0.070 |
Why?
|
| Statistics, Nonparametric | 3 | 2013 | 311 | 0.070 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 2010 | 319 | 0.060 |
Why?
|
| Genetic Therapy | 1 | 2009 | 382 | 0.060 |
Why?
|
| Clinical Trials as Topic | 1 | 2012 | 1178 | 0.060 |
Why?
|
| Pyrroles | 2 | 2004 | 172 | 0.060 |
Why?
|
| Pyridines | 1 | 2008 | 319 | 0.060 |
Why?
|
| Hypoxia | 2 | 2022 | 682 | 0.060 |
Why?
|
| Kidney | 4 | 1996 | 1156 | 0.060 |
Why?
|
| Carcinoma, Small Cell | 1 | 2007 | 137 | 0.060 |
Why?
|
| Anatomy, Cross-Sectional | 1 | 2006 | 14 | 0.060 |
Why?
|
| Colloids | 1 | 2006 | 28 | 0.060 |
Why?
|
| Emulsions | 1 | 2005 | 19 | 0.060 |
Why?
|
| Observer Variation | 2 | 2020 | 626 | 0.060 |
Why?
|
| Proto-Oncogene Proteins c-met | 1 | 2007 | 201 | 0.060 |
Why?
|
| Uganda | 1 | 2025 | 46 | 0.060 |
Why?
|
| Microfluidics | 1 | 2006 | 57 | 0.060 |
Why?
|
| Models, Chemical | 1 | 2006 | 187 | 0.060 |
Why?
|
| Practice Guidelines as Topic | 1 | 2012 | 1096 | 0.060 |
Why?
|
| Carcinoma, Renal Cell | 1 | 2008 | 367 | 0.050 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-2 | 1 | 2004 | 81 | 0.050 |
Why?
|
| Mice, Inbred C57BL | 4 | 2017 | 3490 | 0.050 |
Why?
|
| Colorectal Neoplasms | 1 | 2012 | 1069 | 0.050 |
Why?
|
| Regression Analysis | 2 | 2018 | 599 | 0.050 |
Why?
|
| Melanoma | 2 | 2004 | 497 | 0.050 |
Why?
|
| Blood Flow Velocity | 2 | 1996 | 202 | 0.050 |
Why?
|
| Cell Membrane | 1 | 2005 | 696 | 0.050 |
Why?
|
| Brain Chemistry | 1 | 2002 | 120 | 0.050 |
Why?
|
| Inflammatory Bowel Diseases | 1 | 2009 | 647 | 0.050 |
Why?
|
| Radiologists | 1 | 2022 | 54 | 0.050 |
Why?
|
| Brain Mapping | 1 | 2005 | 594 | 0.050 |
Why?
|
| Pathologists | 1 | 2021 | 40 | 0.040 |
Why?
|
| Logistic Models | 2 | 2018 | 1268 | 0.040 |
Why?
|
| Diffusion | 2 | 2013 | 95 | 0.040 |
Why?
|
| Immunohistochemistry | 3 | 2011 | 1829 | 0.040 |
Why?
|
| Partial Pressure | 2 | 1998 | 51 | 0.040 |
Why?
|
| Radiopharmaceuticals | 1 | 2022 | 204 | 0.040 |
Why?
|
| Hormones | 1 | 2021 | 144 | 0.040 |
Why?
|
| Androgen Antagonists | 1 | 2021 | 144 | 0.040 |
Why?
|
| Antineoplastic Agents | 2 | 2008 | 2422 | 0.040 |
Why?
|
| Radiobiology | 1 | 2000 | 13 | 0.040 |
Why?
|
| Positron Emission Tomography Computed Tomography | 1 | 2021 | 104 | 0.040 |
Why?
|
| Lymphocytes | 2 | 2017 | 489 | 0.040 |
Why?
|
| Swine | 2 | 2012 | 618 | 0.040 |
Why?
|
| Liposomes | 1 | 1979 | 101 | 0.040 |
Why?
|
| Rats, Inbred Strains | 2 | 1989 | 311 | 0.040 |
Why?
|
| Monte Carlo Method | 2 | 2013 | 191 | 0.040 |
Why?
|
| Hydrogen-Ion Concentration | 3 | 2002 | 509 | 0.040 |
Why?
|
| Anisotropy | 1 | 2018 | 65 | 0.040 |
Why?
|
| Microcirculation | 1 | 2018 | 110 | 0.040 |
Why?
|
| Gray Matter | 1 | 2018 | 43 | 0.030 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2007 | 1172 | 0.030 |
Why?
|
| Evans Blue | 1 | 1997 | 4 | 0.030 |
Why?
|
| Deuterium Oxide | 1 | 1997 | 10 | 0.030 |
Why?
|
| Heart | 3 | 1989 | 592 | 0.030 |
Why?
|
| Rats, Sprague-Dawley | 2 | 2013 | 1267 | 0.030 |
Why?
|
| Neoplasm, Residual | 1 | 2018 | 194 | 0.030 |
Why?
|
| Administration, Inhalation | 1 | 1997 | 203 | 0.030 |
Why?
|
| Capillary Permeability | 1 | 1997 | 132 | 0.030 |
Why?
|
| Estradiol | 1 | 2017 | 256 | 0.030 |
Why?
|
| Indazoles | 1 | 2016 | 61 | 0.030 |
Why?
|
| Hemodynamics | 1 | 2020 | 781 | 0.030 |
Why?
|
| Multivariate Analysis | 1 | 2018 | 1010 | 0.030 |
Why?
|
| Tumor Necrosis Factor-alpha | 2 | 1989 | 713 | 0.030 |
Why?
|
| Pathology | 1 | 2015 | 36 | 0.030 |
Why?
|
| Atrophy | 1 | 2015 | 132 | 0.030 |
Why?
|
| Administration, Oral | 1 | 2016 | 688 | 0.030 |
Why?
|
| Statistics as Topic | 1 | 2015 | 236 | 0.030 |
Why?
|
| Hippocampus | 1 | 2018 | 459 | 0.030 |
Why?
|
| Snail Family Transcription Factors | 1 | 2014 | 48 | 0.030 |
Why?
|
| Epithelium | 1 | 2015 | 326 | 0.030 |
Why?
|
| Angiotensin II | 1 | 2014 | 95 | 0.030 |
Why?
|
| Hemoglobins | 1 | 1995 | 196 | 0.030 |
Why?
|
| Models, Animal | 1 | 2015 | 288 | 0.030 |
Why?
|
| Hydralazine | 1 | 1994 | 21 | 0.030 |
Why?
|
| Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2015 | 172 | 0.030 |
Why?
|
| Injections, Subcutaneous | 1 | 1994 | 134 | 0.030 |
Why?
|
| Vascular Endothelial Growth Factor A | 2 | 2007 | 407 | 0.030 |
Why?
|
| Vasodilation | 1 | 1994 | 96 | 0.030 |
Why?
|
| Analysis of Variance | 1 | 2015 | 910 | 0.030 |
Why?
|
| Sugar Phosphates | 2 | 1989 | 8 | 0.020 |
Why?
|
| Predictive Value of Tests | 1 | 2018 | 1807 | 0.020 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 1 | 2014 | 180 | 0.020 |
Why?
|
| Reactive Oxygen Species | 1 | 2015 | 517 | 0.020 |
Why?
|
| Liver Neoplasms | 2 | 2004 | 793 | 0.020 |
Why?
|
| Methylcholanthrene | 1 | 1992 | 10 | 0.020 |
Why?
|
| Pattern Recognition, Automated | 1 | 2013 | 223 | 0.020 |
Why?
|
| Chemoembolization, Therapeutic | 1 | 1992 | 32 | 0.020 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2014 | 466 | 0.020 |
Why?
|
| Mastectomy, Segmental | 1 | 2012 | 108 | 0.020 |
Why?
|
| 2,3-Diphosphoglycerate | 1 | 1991 | 4 | 0.020 |
Why?
|
| Postoperative Period | 1 | 2012 | 318 | 0.020 |
Why?
|
| Diphosphoglyceric Acids | 1 | 1991 | 10 | 0.020 |
Why?
|
| Bayes Theorem | 1 | 2013 | 404 | 0.020 |
Why?
|
| Immunoenzyme Techniques | 1 | 2011 | 298 | 0.020 |
Why?
|
| Risk Assessment | 1 | 2019 | 2480 | 0.020 |
Why?
|
| Tissue Culture Techniques | 1 | 2011 | 82 | 0.020 |
Why?
|
| Groin | 1 | 1991 | 11 | 0.020 |
Why?
|
| Europe | 1 | 2012 | 349 | 0.020 |
Why?
|
| Needs Assessment | 1 | 2012 | 171 | 0.020 |
Why?
|
| Transplantation, Heterologous | 1 | 2012 | 377 | 0.020 |
Why?
|
| Biopsy, Needle | 1 | 2011 | 232 | 0.020 |
Why?
|
| Macrophages | 1 | 2014 | 626 | 0.020 |
Why?
|
| Axilla | 1 | 1991 | 110 | 0.020 |
Why?
|
| Intestines | 1 | 2013 | 431 | 0.020 |
Why?
|
| Iohexol | 1 | 2010 | 23 | 0.020 |
Why?
|
| Models, Structural | 2 | 1990 | 58 | 0.020 |
Why?
|
| Chi-Square Distribution | 1 | 2011 | 363 | 0.020 |
Why?
|
| Hydrogen | 1 | 1990 | 53 | 0.020 |
Why?
|
| Lymphoma | 1 | 1991 | 271 | 0.020 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2018 | 2473 | 0.020 |
Why?
|
| Serum Albumin | 1 | 2009 | 128 | 0.020 |
Why?
|
| Electrocardiography | 1 | 1991 | 522 | 0.020 |
Why?
|
| Rhodamines | 1 | 1988 | 20 | 0.020 |
Why?
|
| Xanthenes | 1 | 1988 | 23 | 0.020 |
Why?
|
| Cell Proliferation | 1 | 2014 | 1761 | 0.020 |
Why?
|
| Placebos | 1 | 2008 | 213 | 0.020 |
Why?
|
| Rheology | 1 | 1988 | 42 | 0.020 |
Why?
|
| Leiomyoma | 1 | 2012 | 211 | 0.020 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 1992 | 426 | 0.020 |
Why?
|
| Injections, Intra-Arterial | 1 | 2007 | 34 | 0.020 |
Why?
|
| Ligands | 1 | 2009 | 478 | 0.020 |
Why?
|
| Liver Diseases | 1 | 1989 | 249 | 0.020 |
Why?
|
| Uterine Neoplasms | 1 | 2012 | 278 | 0.020 |
Why?
|
| Thrombospondin 1 | 1 | 2007 | 22 | 0.020 |
Why?
|
| Cell Growth Processes | 1 | 2007 | 85 | 0.020 |
Why?
|
| Materials Testing | 1 | 2006 | 94 | 0.020 |
Why?
|
| Evaluation Studies as Topic | 1 | 2006 | 271 | 0.020 |
Why?
|
| Mutation | 1 | 2018 | 4374 | 0.020 |
Why?
|
| Kidney Transplantation | 2 | 1990 | 882 | 0.020 |
Why?
|
| Transcription Factors | 1 | 2014 | 1730 | 0.020 |
Why?
|
| Pregnancy | 1 | 2013 | 3240 | 0.020 |
Why?
|
| Shear Strength | 1 | 2006 | 17 | 0.020 |
Why?
|
| Proportional Hazards Models | 1 | 2008 | 901 | 0.020 |
Why?
|
| Electroporation | 1 | 2005 | 57 | 0.010 |
Why?
|
| Particle Size | 1 | 2006 | 126 | 0.010 |
Why?
|
| Combined Modality Therapy | 1 | 2009 | 1773 | 0.010 |
Why?
|
| Equipment Design | 1 | 2006 | 427 | 0.010 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2007 | 535 | 0.010 |
Why?
|
| Survival Analysis | 1 | 2008 | 1546 | 0.010 |
Why?
|
| Stress, Mechanical | 1 | 2006 | 261 | 0.010 |
Why?
|
| Double-Blind Method | 1 | 2008 | 1791 | 0.010 |
Why?
|
| Head and Neck Neoplasms | 1 | 1991 | 1089 | 0.010 |
Why?
|
| Signal Transduction | 1 | 2014 | 3586 | 0.010 |
Why?
|
| Calibration | 1 | 2003 | 108 | 0.010 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2004 | 303 | 0.010 |
Why?
|
| Quality Control | 1 | 2002 | 125 | 0.010 |
Why?
|
| Sample Size | 1 | 2002 | 128 | 0.010 |
Why?
|
| Glucose | 1 | 2004 | 701 | 0.010 |
Why?
|
| Mesothelioma | 1 | 2004 | 333 | 0.010 |
Why?
|
| Iodides | 1 | 1979 | 18 | 0.010 |
Why?
|
| Cardiolipins | 1 | 1979 | 18 | 0.010 |
Why?
|
| Pulmonary Surfactants | 1 | 1979 | 22 | 0.010 |
Why?
|
| Phosphatidylcholines | 1 | 1979 | 53 | 0.010 |
Why?
|
| Spectrometry, Fluorescence | 1 | 1979 | 85 | 0.010 |
Why?
|
| Temperature | 1 | 1979 | 426 | 0.010 |
Why?
|
| Hydrocarbons, Brominated | 1 | 1996 | 4 | 0.010 |
Why?
|
| Cyclic N-Oxides | 1 | 1996 | 33 | 0.010 |
Why?
|
| Drug Combinations | 1 | 1996 | 214 | 0.010 |
Why?
|
| Oximetry | 1 | 1996 | 91 | 0.010 |
Why?
|
| Cell Division | 1 | 1996 | 705 | 0.010 |
Why?
|
| Apoptosis | 1 | 2000 | 1763 | 0.010 |
Why?
|
| Cell Line | 1 | 1996 | 2533 | 0.010 |
Why?
|
| Oxidative Phosphorylation | 1 | 1990 | 64 | 0.010 |
Why?
|
| Esters | 1 | 1990 | 31 | 0.000 |
Why?
|
| Magnetics | 1 | 1989 | 43 | 0.000 |
Why?
|
| Rhodamine 123 | 1 | 1988 | 8 | 0.000 |
Why?
|
| Dimethyl Sulfoxide | 1 | 1988 | 41 | 0.000 |
Why?
|
| Recombinant Proteins | 1 | 1989 | 1034 | 0.000 |
Why?
|
| Mice, Inbred BALB C | 1 | 1989 | 1125 | 0.000 |
Why?
|
| Energy Metabolism | 1 | 1988 | 313 | 0.000 |
Why?
|